70% of biotech acquisitions destroy value. The ones that don't share one thing in common: rigorous pre-acquisition intelligence. Our MBA-level, 5-dimension assessment gives you the strategic clarity to negotiate harder, structure smarter, and walk away when you should.
The Stakes
of M&A deals fail to create value above cost of capital
McKinsey M&A Practice, 2023
in shareholder value destroyed by failed M&A in the last decade
Harvard Business Review, 2022
of acquirers say they would have paid less with better pre-deal intelligence
Bain M&A Survey, 2023
We surface the issues that kill deals post-close — hidden liabilities, IP gaps, key-person risk — before you're locked in.
We contextualize the deal price against comparable transactions and risk-adjusted return expectations. Know if you're overpaying before you sign.
We identify every structural weakness in the target's position — cash runway, competitive dynamics, funding history — and turn them into negotiating tools.
Cash vs. earnout, CVR structures, escrow provisions, milestone triggers — we recommend the structure that protects your capital.
Cultural misalignment kills more deals than bad science. We assess integration complexity before you're committed to the cost.
We identify and frame the synergy sources that justify the premium — and the ones that are wishful thinking.
M&A Intelligence Assessment
6 steps. ~10 minutes. MBA-level deal intelligence grounded in McKinsey, EY, BCG, and Bain M&A research.
Step 1 of 6
Confidentiality: Use a deal code name only. Do not enter company names, ticker symbols, or identifying information. This protects deal confidentiality and your legal obligations.
Why does this deal make strategic sense? Pipeline gap, platform access, geographic expansion, talent acquisition, defensive move?
0/500
Legal Disclaimer: The Bridge BioHealth M&A Pre-Acquisition Intelligence tool is provided for strategic decision-support purposes only and does not constitute financial, legal, investment, or M&A advisory advice. Bridge BioHealth Consulting LLC is not a registered investment advisor or broker-dealer. This tool does not constitute a fairness opinion or valuation opinion. All deal decisions should be independently verified by qualified legal, financial, and scientific advisors. © 2026 Bridge BioHealth Consulting LLC.